Abstract
To the Editor: Recently, trials of adjuvant therapy for melanoma in which therapies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or BRAF and MEK are assessed have reported positive results in terms of relapse-free survival and distant metastasis–free survival.1-4 The European Organization for Research and Treatment of Cancer (EORTC) 18071 trial1 compared ipilimumab with placebo in patients with resected stage III melanoma; the CheckMate 238 trial2 compared nivolumab with ipilimumab in patients with resected stage IIIB, IIIC, or IV melanoma; and the COMBI-AD trial (Nov. 9, 2017, issue)3,4 compared dabrafenib plus trametinib with placebo in patients . . .